DAA Era Linked with Better Liver Transplant Outcomes

This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.

HCV treatment improvements reflected in graft, patient survival

WASHINGTON — Patients with chronic hepatitis C have done better after liver transplant in the era of direct-acting agents (DAAs) against the virus, a researcher said here.

In a retrospective analysis of transplant outcomes, the DAA era was associated with a 36% drop in mortality a year after transplant, according to George Cholankeril, MD, of the University of Tennessee Health Science Center in Memphis.

Also, the proportion of patients whose graft survived the first year rose significantly, Cholankeril reported here at the Liver Meeting, the annual conference of the American Association for the Study of Liver Diseases (AASLD).

The findings were to be expected but “it’s good to see,” commented AASLD plenary session co-moderator Michael Charlton, MD, of the University of Chicago.